Sign in
Taking people in South KoreaNo phase

Phone-based sound therapy BELL-001 for adults with insomnia over 12 weeks

Tests the BELL-001 smartphone sound device in adults with insomnia.

Key facts

Who runs it
BELL Therapeutics Inc.
Where
Incheon, Seongnam-si, and Seoul, South KoreaSee the 3 sites
Trial code
Registry title
Clinical Investigation to Observe the Long-term Safety and Efficacy of the Digital Medical Device 'BELL-001' in Patients Diagnosed With Insomnia
Status
Recruiting
People taking part
40 people, planned
Started
20 Jul 2026
Expected to end
Dec 2026
Type of study
Interventional
Treatments tested
  • BELL-001 Digital Therapeutic
Record updated
28 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diagnosed insomnia. They will use BELL-001, a smartphone app that plays sounds timed to their breathing before sleep, for 12 weeks.

Age
19 to 75 years
Sex
All sexes
Disease stage
Diagnosed insomnia (ICD-10 F51.0 or G47.0) with an Insomnia Severity Index (ISI) score ≥ 15. The sleep diary must show at least 3 nights in the past 7 days with 30 minutes or more to fall asleep, or 60 minutes or more awake after falling asleep.
Earlier treatment
People must agree not to start any other insomnia treatment during the trial, except cognitive behavioral therapy for insomnia. People cannot join if they changed the type or dose of sleep medicines, antidepressants, anticonvulsants, anxiolytics or antipsychotics within 4 weeks before the baseline visit. People cannot join if they took as-needed sleep medicines during screening. People cannot join if they used BELL-001 before, or other investigational drugs or digital devices within 3 months.

Main reasons for not taking part

  • Severe mental illness, including major depressive disorder
  • Other sleep disorders such as narcolepsy, obstructive sleep apnea, restless legs syndrome, or shift work sleep disorder
  • Serious or unstable physical illness, such as heart failure, COPD, stroke or dementia
  • Moderate or worse hearing loss in both ears, or ongoing ringing in the ears (tinnitus)
  • Insomnia caused by medicines, drugs or alcohol, or suspected dependence on sleep medicines

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Diagnosed with ICD-10 nonorganic insomnia (F51.0) or sleep initiation and maintenance disorder (insomnia, G47.0)
  • Insomnia Severity Index (ISI) score ≥ 15
  • Adults aged 19 to 75 years
  • Capable of using a smartphone or tablet and has access to a stable internet connection
  • Willing to provide written informed consent voluntarily and able to comply with all study procedures
  • Agrees not to initiate any other insomnia treatment other than cognitive behavioral therapy for insomnia during the trial
  • Has completed sleep diary entries for at least 3 out of 7 days from the day after the screening visit through the day of the baseline visit (Visit 2)
  • At the baseline visit (Visit 2), sleep diary data from the preceding 7 days confirms at least 3 nights with a sleep onset latency of 30 minutes or more, or wake after sleep onset of 60 minutes or more

Who cannot take part

  • Individuals whose insomnia symptoms are considered to be caused or exacerbated by the physiological effects of medications (prescription drugs or substances of abuse) or alcohol
  • Individuals suspected of sleep medication dependence at the investigator's discretion
  • Individuals with a history of change in the type or dosage of sleep medications, antidepressants, anticonvulsants, anxiolytics, or antipsychotics within 4 weeks prior to the baseline visit (Visit 2)
  • Individuals who took PRN (as-needed) sleep medications during the screening period (including the day before Visit 1)
  • Individuals who used other investigational drugs or investigational digital medical devices within 3 months prior to Visit 1 I-ndividuals with prior experience using BELL-001
  • Individuals with severe psychiatric disorders, including major depressive disorder
  • Individuals diagnosed with or suspected of having insomnia comorbid with narcolepsy (G47.4), obstructive sleep apnea (G47.30), restless legs syndrome (G25.81), periodic limb movement disorder (G47.61), or REM sleep behavior disorder (G47.52) per ICD-10-CM codes
  • Individuals with active physical illness or unstable medical conditions that interfere with activities of daily living, including congestive heart failure, chronic obstructive pulmonary disease (COPD), acute pain, cerebrovascular disease (e.g., stroke), or neurodegenerative disorders (e.g., dementia, multiple sclerosis)
  • Individuals deemed by the investigator to be unable to participate in the study due to respiratory conditions such as asthma
  • Individuals diagnosed with shift work sleep-wake disorder, or those who experience periodic insomnia or sleep-wake rhythm disturbance due to a work environment requiring repeated circadian readjustment, such as day/night shift rotation or frequent international travel
  • Individuals with moderate or greater hearing loss in both ears
  • Individuals currently reporting persistent tinnitus symptoms
  • Individuals deemed inappropriate for participation in the clinical trial by the investigator for any other reason

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 19 and 75 years old?

Where in South Korea

  • Catholic Kwandong University International St.Mary's HospitalIncheon, South KoreaContact: Hye-Yoon KimTaking people
  • CHA Bundang HospitalSeongnam-si, South KoreaContact: Jungwon ShinTaking people
  • Seoul National University Hospital, Seoul, 03080Seoul, South KoreaContact: Ki-young JungTaking people

About the trial

What the trial wants to find out

This study is a multicenter, single-arm, prospective clinical trial designed to observe the long-term safety and effectiveness of the digital medical device BELL-001 in patients diagnosed with insomnia. Insomnia is a common sleep disorder that can significantly affect daytime functioning, mood, and overall quality of life. Many patients continue to experience difficulties despite lifestyle modifications or pharmacological treatment, and there is a growing need for safer, non-pharmacological therapeutic options.

Read full original descriptionShow less

BELL-001 is a smartphone-based therapeutic device that delivers personalized auditory stimulation during the pre-sleep period. The device is designed to promote relaxation and support the transition into sleep by analyzing individual breathing patterns and providing synchronized sound feedback. This study evaluates the long-term safety and effectiveness of BELL-001 over approximately 3 months (12 weeks) of use.

Forty adults diagnosed with insomnia will participate as the BELL-001 group. Participants will use the device for 12 weeks. During the study period, insomnia severity, depression, anxiety, and work productivity will be assessed. The outcome measures include changes in the Insomnia Severity Index (ISI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and Work Productivity and Activity Impairment Questionnaire (WPAI) at 4, 8, and 12 weeks compared to baseline; changes in Total Sleep Time (TST), Sleep Onset Latency (SOL), Wake After Sleep Onset (WASO), and sleep stage ratios measured via Nearable Device at 4, 8, and 12 weeks; and changes in subjective Sleep Latency (sSL), subjective Sleep Quality (sSQ), subjective Wake After Sleep Onset (sWASO), subjective number of awakenings after sleep onset, subjective Sleep Efficiency (sSE), and subjective Total Sleep Time (sTST) assessed through sleep diaries at 4, 8, and 12 weeks compared to baseline. Safety will be evaluated over the 12-week period. Additional outcome measures will include assessment of compliance and satisfaction.

This clinical trial is conducted at multiple hospitals in Korea and adheres to ethical guidelines, including review and approval by Institutional Review Boards (IRBs). Participation is voluntary, and all individuals will provide informed consent prior to the initiation of any study procedures. The results of this study are expected to provide key evidence for the clinical application of a digital, non-pharmacological intervention for adults with insomnia.

The group in the trial

  • BELL-001 Digital TherapeuticTreatment being tested

    Participants assigned to the experimental arm will use BELL-001, a smartphone-based digital therapeutic designed to provide personalized auditory stimulation synchronized with the user's breathing pattern. The intervention is administered nightly during the pre-sleep period for 12 weeks. The device delivers an active algorithm intended to reduce pre-sleep hyperarousal and support sleep initiation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Single-arm, Prospective Clinical Investigation to Observe the Long-term Safety and Efficacy of the Digital Medical Device 'BELL-001' in Patients Diagnosed With Insomnia
Plain-language title
Phone-based sound therapy BELL-001 for adults with insomnia over 12 weeksGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07582809, who can take part
Record updated
28 August 2026